SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Dillner Joakim) "

Sökning: WFRF:(Dillner Joakim)

  • Resultat 61-70 av 271
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  • Dillner, Joakim (författare)
  • Att förebygga livmoderhalscancer: Gynekologisk cellprovtagning samt vaccination mot Papillomvirus.
  • 2004
  • Ingår i: Incitament. - 1103-503X. ; 4, s. 261-265
  • Tidskriftsartikel (refereegranskat)abstract
    • En förutsättning för insjuknande i cervixcancer är en infektion med genitalt papillomvirus - HPV. Sjukdomen uppstår efter åratal av förstadier, som kan upptäckas genom cervixcytologi/gynekologisk cellprovstagning och stoppas med behandling. I Sverige har cellprovstagningen minskat förekomsten av livmoderhalscancer med 50 procent. I Finland, där man använder organiserad screening, har förekomsten minskat med 80 procent. Organiserad cellprovstagning är hälsoekonomiskt lönsamt.
  •  
62.
  • Dillner, Joakim, et al. (författare)
  • Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?
  • 2004
  • Ingår i: Expert Reviews in Molecular Medicine. - 1462-3994. ; 2004, s. 1-21
  • Tidskriftsartikel (refereegranskat)abstract
    • Human papillomavirus (HPV) infection is the cause of squamous cell carcinoma of the uterine cervix. This causative relationship has provided the rationale and incentive for development of a prophylactic vaccine. Such a vaccine, if found to be effective, could reduce the need for cervical cancer screening and have a profound effect on the incidence of cervical and other anogenital cancers. This review begins by examining the basic biological and epidemiological principles relevant to the development of HPV preventative vaccines. It then summarises studies examining the use of vaccines to prevent HPV infection in animals and humans, and, finally, discusses some of the unanswered issues surrounding vaccine development against HPV infection and cervical cancer.
  •  
63.
  • Dillner, Joakim, et al. (författare)
  • Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies.
  • 2006
  • Ingår i: International Journal of Cancer. - : Wiley. - 0020-7136 .- 1097-0215. ; 119:5, s. 1108-1124
  • Tidskriftsartikel (refereegranskat)abstract
    • The International Collaboration of Epidemiological Studies of Cervical Cancer has combined individual data on 11,161 women with invasive carcinoma, 5,402 women with cervical intraepithelial neoplasia (CIN)3/carcinoma in situ and 33,542 women without cervical carcinoma from 25 epidemiological studies. Relative risks (RRs) and 95% confidence intervals (CIs) of cervical carcinoma in relation to number of full-term pregnancies, and age at first full-term pregnancy, were calculated conditioning by study, age, lifetime number of sexual partners and age at first sexual intercourse. Number of full-term pregnancies was associated with a risk of invasive cervical carcinoma. After controlling for age at first full-term pregnancy, the RR for invasive cervical carcinoma among parous women was 1.76 (95% CI: 1.53-2.02) for 7 full-term pregnancies compared with 1-2. For CIN3/carcinoma in situ, no significant trend was found with increasing number of births after controlling for age at first full-term pregnancy among parous women. Early age at first full-term pregnancy was also associated with risk of both invasive cervical carcinoma and CIN3/carcinoma in situ. After controlling for number of full-term pregnancies, the RR for first full-term pregnancy at age <17 years compared with 25 years was 1.77 (95% CI: 1.42-2.23) for invasive cervical carcinoma, and 1.78 (95% CI: 1.26-2.51) for CIN3/carcinoma in situ. Results were similar in analyses restricted to high-risk human papilloma virus (HPV)-positive cases and controls. No relationship was found between cervical HPV positivity and number of full-term pregnancies, or age at first full-term pregnancy among controls. Differences in reproductive habits may have contributed to differences in cervical cancer incidence between developed and developing countries
  •  
64.
  •  
65.
  • Dillner, Joakim, et al. (författare)
  • Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
  • 2010
  • Ingår i: BMJ: British Medical Journal. - : BMJ. - 1756-1833 .- 0959-8138 .- 1468-5833. ; 341
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata). DESIGN: Data from two international, double blind, placebo controlled, randomised efficacy trials of quadrivalent HPV vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)). The trials were to be 4 years in length, and the results reported are from final study data of 42 months' follow-up. SETTING: Primary care centres and university or hospital associated health centres in 24 countries and territories around the world. PARTICIPANTS: 17 622 women aged 16-26 years enrolled between December 2001 and May 2003. Major exclusion criteria were lifetime number of sexual partners (>4), history of abnormal cervical smear test results, and pregnancy. INTERVENTION: Three doses of quadrivalent HPV vaccine (for serotypes 6, 11, 16, and 18) or placebo at day 1, month 2, and month 6. MAIN OUTCOME MEASURES: Vaccine efficacy against cervical, vulvar, and vaginal intraepithelial neoplasia grade I and condyloma in a per protocol susceptible population that included subjects who received all three vaccine doses, tested negative for the relevant vaccine HPV types at day 1 and remained negative through month 7, and had no major protocol violations. Intention to treat, generally HPV naive, and unrestricted susceptible populations were also studied. RESULTS: In the per protocol susceptible population, vaccine efficacy against lesions related to the HPV types in the vaccine was 96% for cervical intraepithelial neoplasia grade I (95% confidence interval 91% to 98%), 100% for both vulvar and vaginal intraepithelial neoplasia grade I (95% CIs 74% to 100%, 64% to 100% respectively), and 99% for condyloma (96% to 100%). Vaccine efficacy against any lesion (regardless of HPV type) in the generally naive population was 30% (17% to 41%), 75% (22% to 94%), and 48% (10% to 71%) for cervical, vulvar, and vaginal intraepithelial neoplasia grade I, respectively, and 83% (74% to 89%) for condyloma. CONCLUSIONS: Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18) and a substantial reduction in the burden of these diseases through 42 months of follow-up. TRIAL REGISTRATIONS: NCT00092521 and NCT00092534.
  •  
66.
  • Dillner, Joakim (författare)
  • Infektioner som kan framkalla cancer.
  • 2004
  • Ingår i: Cancerforskning i Region Skåne och södra sjukvårdsregionen. ; , s. 34-43
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
67.
  • Dillner, Joakim, et al. (författare)
  • Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.
  • 2008
  • Ingår i: BMJ: British Medical Journal. - : BMJ. - 1756-1833 .- 0959-8138 .- 1468-5833. ; 337
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To obtain large scale and generalisable data on the long term predictive value of cytology and human papillomavirus (HPV) testing for development of cervical intraepithelial neoplasia grade 3 or cancer (CIN3+). DESIGN: Multinational cohort study with joint database analysis. SETTING: Seven primary HPV screening studies in six European countries. PARTICIPANTS: 24,295 women attending cervical screening enrolled into HPV screening trials who had at least one cervical cytology or histopathology examination during follow-up. MAIN OUTCOME MEASURE: Long term cumulative incidence of CIN3+. RESULTS: The cumulative incidence rate of CIN3+ after six years was considerably lower among women negative for HPV at baseline (0.27%, 95% confidence interval 0.12% to 0.45%) than among women with negative results on cytology (0.97%, 0.53% to 1.34%)). By comparison, the cumulative incidence rate for women with negative cytology results at the most commonly recommended screening interval in Europe (three years) was 0.51% (0.23% to 0.77%). The cumulative incidence rate among women with negative cytology results who were positive for HPV increased continuously over time, reaching 10% at six years, whereas the rate among women with positive cytology results who were negative for HPV remained below 3%. CONCLUSIONS: A consistently low six year cumulative incidence rate of CIN3+ among women negative for HPV suggests that cervical screening strategies in which women are screened for HPV every six years are safe and effective.
  •  
68.
  •  
69.
  •  
70.
  • Dillner, Joakim, et al. (författare)
  • Svensk konsensus om vaccination mot cervixcancer. Vaccinprogram bör införas i grundskolan med sikte på att utrota HPV16/18
  • 2006
  • Ingår i: Läkartidningen. - 0023-7205. ; 103:44, s. 9-3377
  • Tidskriftsartikel (refereegranskat)abstract
    • Vaccination against the Human Papillomavirus (HPV) has recently been approved as a means to prevent cervical cancer. The Swedish Institute for Infectious Disease Control and the Swedish Society for Obstetrics & Gynecology arranged a consensus conference to discuss design of future cervical cancer prevention programs. Conclusions include that preventive programs should aim at eradication of oncogenic HPV 16/18 infection and that the potentially preventable cervical cancers should no longer occur. Necessary prerequisites include adoption of a population-based vaccination program in primary school, an HPV vaccination registry and coordination of cervical cancer preventive efforts on vaccination and cervical screening.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 271
Typ av publikation
tidskriftsartikel (249)
konferensbidrag (8)
forskningsöversikt (8)
bokkapitel (4)
annan publikation (2)
Typ av innehåll
refereegranskat (260)
övrigt vetenskapligt/konstnärligt (11)
Författare/redaktör
Dillner, Joakim (271)
Forslund, Ola (46)
Lehtinen, Matti (40)
Hallmans, Göran (20)
Ekström, Johanna (20)
Eklund, Carina (20)
visa fler...
Sparén, Pär (19)
Luostarinen, Tapio (19)
Paavonen, Jorma (17)
Bzhalava, Davit (15)
Faust, Helena (15)
Wadell, Göran (13)
Andersson, Kristin (13)
Andrae, Bengt (13)
Lagheden, Camilla (13)
Stattin, Pär (12)
Sundström, Karin (12)
Carlson, Joyce (12)
Bosch, F. Xavier (12)
Ploner, Alexander (11)
Söderlund Strand, An ... (11)
Hakama, Matti (11)
Pukkala, Eero (11)
Pawlita, Michael (10)
Thoresen, Steinar (10)
Brown, Darron R. (10)
Koutsky, Laura A. (10)
Ault, Kevin A. (10)
Ferris, Daron G. (10)
Villa, Luisa L. (10)
Lehtinen, M (9)
Hultin, Emilie (9)
Kjaer, Susanne K. (9)
Sigurdsson, Kristjan (9)
Hernandez-Avila, Mau ... (9)
Wheeler, Cosette M. (9)
Perez, Gonzalo (9)
Tay, Eng Hseon (9)
Majewski, Slawomir (9)
Munoz, Nubia (9)
Myers, Evan R. (9)
Taddeo, Frank J. (9)
Tadesse, Amha (9)
Hakulinen, Timo (8)
Törnberg, Sven (8)
Arbyn, Marc (8)
Naucler, Pontus (8)
Waterboer, Tim (8)
Dillner, Lena (8)
Garland, Suzanne M. (8)
visa färre...
Lärosäte
Karolinska Institutet (245)
Lunds universitet (238)
Umeå universitet (48)
Uppsala universitet (25)
Göteborgs universitet (18)
Linköpings universitet (7)
visa fler...
Kungliga Tekniska Högskolan (6)
Stockholms universitet (2)
Chalmers tekniska högskola (2)
Örebro universitet (1)
visa färre...
Språk
Engelska (263)
Svenska (8)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (261)
Naturvetenskap (10)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy